Share on StockTwits

Shares of Zogenix (NASDAQ:ZGNX) were the target of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 20,271,501 shares, an increase of 12.6% from the April 15th total of 18,006,401 shares, AnalystRatings.Net reports. Approximately 17.8% of the company’s stock are short sold. Based on an average daily trading volume, of 3,207,468 shares, the short-interest ratio is presently 6.3 days.

A number of research firms have recently commented on ZGNX. Analysts at William Blair reiterated an “outperform” rating on shares of Zogenix in a research note on Monday. They now have a $5.00 price target on the stock, down previously from $6.00. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Zogenix in a research note on Friday, April 25th. They now have a $5.00 price target on the stock.

Shares of Zogenix (NASDAQ:ZGNX) opened at 2.28 on Wednesday. Zogenix has a 52-week low of $1.25 and a 52-week high of $5.19. The stock has a 50-day moving average of $2.63 and a 200-day moving average of $3.38. The company’s market cap is $318.1 million.

Zogenix (NASDAQ:ZGNX) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.67 earnings per share for the current fiscal year.

Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.